Chemed stock jumped 4.2% to about US$539 by the close, which indicates that the market responded positively to the results, but the headline story runs deeper than a single-day move. Q2 adjusted earnings outpaced recent history, with adjusted diluted earnings per share up sharply year on year and VITAS hospice margins comfortably above internal expectations.

For you as a shareholder, the key point is how those hospice economics influence the longer-term view. Forecast earnings growth, solid cash generation and a P/E sitting below many healthcare peers now sit alongside this stronger quarter. Together, these factors frame the valuation debate that follows.

Is Chemed trading at a genuine discount to its estimated US$680.94 future cash…